Search Medical Condition
Please enter condition
Please choose location from dropdown
 

Milan, Italy Clinical Trials

A listing of Milan, Italy clinical trials actively recruiting patients volunteers.

RESULTS

Found (900) clinical trials

TK008: Efficacy Study on the Strategy of HSV-Tk Engineering Donor Lymphocytes to Treat Patients With High Risk Acute Leukemia

Delayed immune-reconstitution remains one of the main limitation of haploidentical stem cell transplantation. The risk of severe infections remains high for several months and CD3+ reconstitution could take more than 10 months. The low number of lymphocytes infused with the graft, the degree of HLA (Human Leukocyte Antigen) disparity, and ...

Phase

0.0 miles

Learn More »

Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP.

This is a prospective, multicenter, two-arm randomized phase II screening trial34 in young patients (18-65 years) affected by relapsed/refractory Diffuse Large B-cell Lymphoma (DLBCL) at diagnosis, eligible to high-dose therapy. Aim of the study is to to assess whether the addition of Bortezomib to R-DHAP is more promising than standard ...

Phase

0.0 miles

Learn More »

Ph II Cabazitaxel DD Liposarcoma

Soft tissue sarcomas (STS) are a rare group of malignant heterogenous tumors (> 50 histological subtypes, including liposarcoma, the commonest subtype of STS) with distinct genetic, pathological and clinical profiles, and varying patterns of tumor spread. The optimal cytotoxic treatment for this group of patients remains uncertain. Single agents which ...

Phase

0.0 miles

Learn More »

Observational Study to Evaluate Vandetanib in RET -/+ Patients With Metastatic Medullary Thyroid Cancer

This is a multinational, multicenter, non-interventional (observational) and prospective study. European countries where vandetanib is on the market will participate in the study. This study is being conducted to fulfil the specific obligation post-authorisation measure for the conditional marketing authorisation. It is carried on to confirm in real life conditions ...

Phase N/A

0.0 miles

Learn More »

Efficacy and Safety Study as Add-on Therapy of SA237 to Treat NMO and NMOSD

Recruitment is closed to adults. Recruitment is open to adolescents 12-17 years old.

Phase

0.0 miles

Learn More »

Pharmacokinetic Efficacy and Safety of BT524 in Patients With Congenital Fibrinogen Deficiency

The present study is designed as a prospective, open-label, multicentre, phase I/III study investigating the 14 day single-dose pharmacokinetic properties, efficacy and safety of BT524 following intravenous administration in the treatment or prophylaxis of bleeding in patients with congenital afibrinogenemia or severe congenital hypofibrinogenemia.

Phase

0.0 miles

Learn More »

hATG+CsA vs hATG+CsA+Eltrombopag for SAA

This is a superiority trial aiming to increase the 3 month complete response rate. The sample size is calculated on the hypothesis that the experimental treatment will increase the 3 months response rate up to 21% (by 3 folds, based on the 7% reported in Scheinberg et al [17]). Under ...

Phase

0.0 miles

Learn More »

A Study Comparing the Efficacy and Safety of Etrolizumab to Infliximab in Participants With Moderate to Severe Ulcerative Colitis Who Are Na ve to Tumor Necrosis Factor (TNF) Inhibitors

This is a multicenter, Phase III, randomized, double-blind, double-dummy, parallel-group study to evaluate the safety, efficacy, and tolerability of etrolizumab compared with infliximab in treating participants with moderate to severe ulcerative colitis (UC) who are naive to tumor necrosis factor (TNF) inhibitors. Participants will be randomized in a 1:1 ratio ...

Phase

0.0 miles

Learn More »

Eltrombopag in Patients With Delayed Post Transplant Thrombocytopenia.

The incidence of delayed thrombocytopenia in patients who undergo allogeneic hemopoietic stem cell transplant (SCT) is nearly 20-40% (1-2). Chronic graft versus host disease (cGVHD) seems to be the most frequent pathologic condition associated with post SCT delayed thrombocytopenia. Previous studies indicated the occurrence of delayed thrombocytopenia as a poor ...

Phase

0.0 miles

Learn More »

Patients are needed to participate in a clinical research study for the treatment of Breast Cancer

IBC IBC is a rare but rapidly growing form of breast cancer. Currently, there are no known risk factors and biological features (such as in the genes) that researchers can use to help design better treatments for IBC. Study Participation: If you are diagnosed with IBC or the doctor believes ...

Phase N/A

0.0 miles

Learn More »